1.
AJNR Am J Neuroradiol
; 31(9): 1588-90, 2010 Oct.
Article
in English
| MEDLINE
| ID: mdl-20688889
ABSTRACT
Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/immunology , Brain/immunology , Leukocytes/immunology , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Animals , Antibodies, Monoclonal, Humanized , Brain/drug effects , Cell Adhesion/drug effects , Cell Adhesion/immunology , Cell Migration Inhibition/drug effects , Cell Migration Inhibition/immunology , Humans , Leukocytes/drug effects , Models, Immunological , Natalizumab
2.
AJNR Am J Neuroradiol
; 31(7): 1178-80, 2010 Aug.
Article
in English
| MEDLINE
| ID: mdl-20448016
ABSTRACT
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
